Return patients living with chronic wounds to healing sooner

E Galea
Ugo Medical, Urgo Education & Training Alliance

 Wound Healing Southern Africa 2023;16(1):22

Summary

Technology Lipido-Colloid with nano-oligosaccharide factor (TLC-NOSF) range's efficacy in healing significantly sooner has been demonstrated in the highest level of clinical studies (double-blind, randomised controlled trials)[1,2] and through observational studies.[3] These studies have also demonstrated that the earlier the TLC-NOSF (UrgoStart) treatment range is initiated, the more effective it is for complex and first-intention wounds.[2,3]

Technology Lipido-Colloid (TLC) comprises a matrix containing hydrocolloid and lipophilic substances, which have been shown in vitro to enable the proliferation of fibroblasts, stimulate extracellular matrix production and contribute to the formation of new tissue through the creation of a moist environment.[4,5] NOSF is a new compound aiming to promote wound closure mainly through the reduction of matrix metalloproteinase (MMP) activity. This factor is incorporated within the TLC matrix and locally released in the wound.[6]

Leg ulcers, diabetic foot ulcers and pressure injuries take an average of 210 days to heal.[7] TLC-NOSF is a local treatment that has been shown to be effective at every wound phase, reducing healing time by an average of 100 days.[3]

TLC-NOSF is included in three systematic reviews as well as incorporated in the International Working Group for Diabetic Foot (IWGDF) and the National Institute for Health and Care Excellence (NICE) (UK) recommendations, amongst other high-level and real-life publications.[8-12]

This poster presentation will give an overview of the evidence behind TLC-NOSF and practical guidance for including this treatment for chronic wounds in daily practice.

References

1. Edmonds M, Lázaro-Martínez J, Alfayate-García, et al. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018;6(3):186-96. https://doi.org/10.1016/s2213-8587(17)30438-2.
2. Lázaro-Martínez JL, Edmands M, Rayman G, et al. Optimal wound closure of diabetic foot ulcers with early initiation of TLC-NOSF treatment: post-hoc analysis of Explorer. J Wound Care. 2019;28(6):358-67. https://doi.org/10.12968/jowc.2019.28.6.358.
3. Münter KC, Meaume S, Augustin M, Senet P, Kérihuel JC. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care. 2017;26(Suppl 2):S4-S15. Erratum in: J Wound Care. 2017;26(3):153. https://doi.org/10.12968/jowc.2017.26.sup2.s4.
4. Bernard FX, Barrault C, Juchaux F, Laurensou C, Apert L. Stimulation of the proliferation of human dermal fibroblasts in vitro by a lipidocolloid dressing. J Wound Care. 2005;14(5):215-20. https://doi.org/10.12968/jowc.2005.14.5.26775.
5. McGrath A, Newton H, Trudgian J, Greenwood M. TLC dressings made easy. Wounds UK. 2014;10(3):1-4.
6. Schmutz JL, Meaume S, Fays S, et al. Evaluation of the nano-oligosaccharide factor lipido-colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. Int Wound J. 2008;5(2):172-82. https://doi.org/10.1111/j.1742-481x.2008.00453.x.
7. Report to the French minister responsible for Social Security and the French Parliament concerning the evolution of French National Health Insurance charges and products for 2014. July 2013. CNAM database: leg ulcers: 210 days; pressure ulcers: 223 days; diabetic foot ulcers: comparative data not available.
8. Dissemond J, Augustin M, Dietlein M, et al. Efficacy of MMP-inhibiting wound dressings in the treatment of chronic wounds: a systematic review. J Wound Care. 2020;29(2):102-18. https://doi.org/10.12968/jowc.2020.29.2.102
9. Nair H, Galea E, Deng W, et al. Benefits of sucrose octasulfate (TLC-NOSF) dressings in the treatment of chronic wounds: a systematic review. J Wound Care. 2021;30(Suppl 4):S42-52. https://doi.org/10.12968/jowc.2021.30.sup4.s42.
10. Vas P, Rayman G, Dhatariya K, et al. Effectiveness of interventions to enhance healing of chronic foot ulcers in diabetes: a systematic review. Diabetes Metab Res Rev. 2020;36 Suppl 1:e3284. https://doi.org/10.1002/dmrr.3284.
11. Schaper NC, Netten JJ, Apelqvist J, et al; IWGDF Editorial Board. Practical guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). Diabetes Metab Res Rev. 2020;36(Suppl 1):e3266. https://doi.org/10.1002/dmrr.3266.
12. National Institute for Health and Care Excellence. UrgoStart for treating diabetic foot ulcers and leg ulcers. Medical technologies guidance; 2019. Available from: https://tinyurl.com/358f3e8d.